A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff UMB Bank may pursue some claims on behalf of the shareholders, including for breach of contract.
(Reporting by Stempel in New York; Editing by Chris Reese)
Copyright 2026 Reuters. Click for restrictions.
Was this article valuable?
Here are more articles you may enjoy.
One out of 10 Cars Sold in Europe Is Now Made by a Chinese Brand 
Hackers Hit Sensitive Targets in 37 Nations in Spying Plot 
Founder of Auto Parts Maker Charged With Fraud That Wiped Out Billions 
LA County Told to Pause $4B in Abuse Payouts as DA Probes Fraud Claims 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.